Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms

Alzheimer's and Dementia: Translational Research and Clinical Interventions - Tập 3 - Trang 440-449 - 2017
Krista L. Lanctôt1, Joan Amatniek2, Sonia Ancoli-Israel3,4, Steven E. Arnold5, Clive Ballard6,7, Jiska Cohen-Mansfield8, Zahinoor Ismail9, Constantine Lyketsos10, David S. Miller11, Erik Musiek12, Ricardo S. Osorio13, Paul B. Rosenberg14, Andrew Satlin15, David Steffens16, Pierre Tariot17, Lisa J. Bain18, Maria C. Carrillo19, James A. Hendrix19, Heidi Jurgens19, Brendon Boot20,21
1Hurvitz Brain Sciences Program, Sunnybrook Research Institute and Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Canada
2Otsuka Pharmaceutical Development & Commercialization, Inc, Princeton, NJ, USA
3Department of Psychiatry, University of California, San Diego, CA, USA
4Department of Medicine, University of California, San Diego, CA, USA
5Interdisciplinary Brain Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA
6Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
7University of Exeter, Exeter, UK
8Department of Health Promotion, School of Public Health, Sackler Faculty of Medicine and Minerva Center for the Interdisciplinary Study of End of Life, Tel Aviv University, Tel Aviv, Israel
9Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada
10Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medicine Institutes, Baltimore, MD, USA
11Bracket Global, Wayne, PA, USA
12Department of Neurology, Hope Center for Neurological Disorders, and Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA
13Center for Brain Health, NYU Langone Medical Center, New York, NY, USA
14Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
15Eisai Inc., Woodcliff Lake, NJ, USA
16Department of Psychiatry, University of Connecticut School of Medicine, Farmington, CT, USA
17Banner Alzheimer's Institute, Phoenix, AZ, USA
18Elverson, PA, USA
19Alzheimer's Association Chicago IL USA
20Department of Neurology, Brigham and Women's Hospital, Harvard University School of Medicine, Boston, MA, USA
21Voyager Therapeutics, Cambridge, MA, USA

Tóm tắt

AbstractNeuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing substantial distress for both people with dementia and their caregivers, and contributing to early institutionalization. They are among the earliest signs and symptoms of neurocognitive disorders and incipient cognitive decline, yet are under‐recognized and often challenging to treat. With this in mind, the Alzheimer's Association convened a Research Roundtable in May 2016, bringing together experts from academia, industry, and regulatory agencies to discuss the latest understanding of NPSs and review the development of therapeutics and biomarkers of NPSs in AD. This review will explore the neurobiology of NPSs in AD and specific symptoms common in AD such as psychosis, agitation, apathy, depression, and sleep disturbances. In addition, clinical trial designs for NPSs in AD and regulatory considerations will be discussed.

Tài liệu tham khảo

10.1016/j.jalz.2011.05.2410 10.1016/j.jalz.2012.12.001 10.1002/gps.1858 10.1097/JGP.0b013e3181faec23 10.1002/gps.1025 10.1176/jnp.9.4.556 10.1002/(SICI)1099-1166(200002)15:2<181::AID-GPS96>3.0.CO;2-I 10.1176/ajp.147.8.1049 10.1176/appi.ajp.2014.14040480 10.1002/(SICI)1099-1166(199909)14:9<701::AID-GPS5>3.0.CO;2-# 10.1212/01.WNL.0000036904.73393.E4 10.1136/bmj.h369 10.31887/DCNS.2015.17.1/bcuthbert 10.1212/WNL.44.12.2308 10.1016/j.jad.2015.09.069 10.2147/CIA.S63504 10.1017/S1041610210000876 10.1016/j.jagp.2014.02.007 10.1097/JGP.0b013e3182107c69 Banks S.J., 2014, The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline, Dement Geriatr Cogn Dis Extra, 4, 509, 10.1159/000357775 10.1176/appi.ajp.2014.13060821 10.1212/01.WNL.0000118301.92105.EE 10.1016/j.jagp.2013.01.006 10.1212/WNL.0000000000001238 10.1016/j.jalz.2015.05.017 10.3233/JAD-160979 Mortby M.E., 2017, Mild behavioral impairment: implications for clinical trials, Int Psychogeriatr 10.1016/j.jalz.2012.01.003 10.1176/appi.ajp.2012.11101529 Cohen‐Mansfield J., 1995, Assessment of disruptive behavior/agitation in the elderly: function, methods, and difficulties, J Geriatr Psychiatry Neurol, 8, 52 10.3928/0098-9134-19990201-08 10.1097/WAD.0b013e3181f811f4 Cohen‐Mansfield J., 2010, Handbook of assessment in clinical gerontology, 381, 10.1016/B978-0-12-374961-1.10015-6 10.1093/cercor/1.1.103 10.1016/0306-4522(90)90408-V 10.1007/s004019900178 10.1016/j.neurobiolaging.2006.02.007 10.1002/ana.20723 10.1016/j.pneurobio.2016.04.001 10.1002/cne.903060406 10.1186/s40478-015-0187-1 10.1097/00019442-200002000-00004 10.1192/bjp.167.4.537 10.1111/j.1532-5415.1997.tb02980.x 10.1097/00019442-200301000-00011 10.1001/archpsyc.57.12.1165 10.3233/JAD-131166 10.1001/archneur.1991.00530180075020 10.1016/j.jns.2007.04.017 10.2174/1567205012666150204130456 10.1016/j.pscychresns.2012.01.008 10.1192/bjp.165.1.53 10.1007/s11920-011-0195-1 10.1176/jnp.9.1.64 10.1097/01.JGP.0000200589.01396.6d 10.1001/jamapsychiatry.2014.3018 10.1016/j.psychres.2011.05.022 Cohen‐Mansfield J., 2017, Rethinking psychosis in dementia: an analysis of antecedents and explanations, Am J Alzheimers Dis Other Demen, 32, 265, 10.1177/1533317517703478 10.1176/appi.ajp.2015.15010130 10.1017/S1041610214001963 10.1016/j.mam.2015.05.005 Tsai C.F., 2013, Differences in brain metabolism associated with agitation and depression in Alzheimer's disease, East Asian Arch Psychiatry, 23, 86 Cohen‐Mansfield J., 2000, Theoretical frameworks for behavioral problems in dementia, Alzheimers Care Q, 1, 18 Cohen‐Mansfield J., 2015, Behavioral and psychological symptoms of dementia, 271 10.4088/JCP.12m07918 10.1007/s11940-013-0257-2 10.1097/j.pain.0000000000000095 10.1136/bmj.d4065 10.1001/jama.2014.93 10.1080/13543784.2017.1267726 10.1002/1099-1166(200102)16:2<192::AID-GPS301>3.0.CO;2-Y 10.3233/JAD-150146 10.1016/j.eurpsy.2008.09.001 10.1016/0165-1781(91)90040-V 10.3233/JAD-2012-112003 10.1016/j.jalz.2016.05.008 10.4088/JCP.12m08099 10.3233/JAD-141983 10.1097/JGP.0b013e3181b0fa13 10.1017/S1041610214001446 10.1002/ajmg.b.10068 10.1001/archpsyc.60.7.737 10.1097/JGP.0b013e3181c796eb 10.1016/S0140-6736(11)60830-1 10.1007/s40266-012-0012-5 10.1159/000316119 10.1097/WAD.0b013e318231e46e 10.2174/15672050113109990134 10.1111/jsr.12054 10.1016/j.jalz.2014.08.104 10.1001/jamaneurol.2013.2334 10.1111/j.1532-5415.2007.01506.x 10.1001/jama.2011.1115 10.1111/j.1532-5415.1991.tb01647.x 10.1212/WNL.0000000000001566 10.1002/ana.22468 10.1172/JCI70317 10.1126/science.1180962 10.1001/archneurol.2012.18107 10.1084/jem.20141788 10.1001/jamaneurol.2014.2510 10.1126/science.1241224 10.1073/pnas.0901435106 10.1016/B978-0-444-53839-0.00018-1 10.1093/cercor/bhq295 10.1523/JNEUROSCI.2015-10.2010 10.1089/brain.2012.0075 10.1093/brain/120.7.1173 10.1523/JNEUROSCI.17-12-04800.1997 10.1016/j.neuron.2005.10.028 10.1002/ana.24672 10.1111/j.1532-5415.2011.03519.x 10.1207/S15402010BSM0101_4 McCleery J., 2014, Pharmacotherapies for sleep disturbances in Alzheimer's disease, Cochrane Database Syst Rev, CD009178 10.1111/j.1532-5415.2008.01934.x 10.1016/j.sleep.2008.12.016 10.1159/000069738 10.1016/j.jagp.2012.10.002 10.1016/j.jalz.2011.01.007
Thông tin
Thông tin xuất bản

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Tập 3

440-449

Thông tin tác giả